JP2023504493A - 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用 - Google Patents
個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用 Download PDFInfo
- Publication number
- JP2023504493A JP2023504493A JP2022532717A JP2022532717A JP2023504493A JP 2023504493 A JP2023504493 A JP 2023504493A JP 2022532717 A JP2022532717 A JP 2022532717A JP 2022532717 A JP2022532717 A JP 2022532717A JP 2023504493 A JP2023504493 A JP 2023504493A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- function
- days
- intestinal flora
- diversity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 265
- 244000005709 gut microbiome Species 0.000 title claims description 57
- 230000000968 intestinal effect Effects 0.000 claims abstract description 113
- 239000000284 extract Substances 0.000 claims abstract description 65
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 48
- 240000004371 Panax ginseng Species 0.000 claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 claims abstract description 36
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 35
- 230000001105 regulatory effect Effects 0.000 claims abstract description 33
- 235000013557 nattō Nutrition 0.000 claims abstract description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 28
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 27
- 210000000952 spleen Anatomy 0.000 claims abstract description 26
- 239000000306 component Substances 0.000 claims abstract description 24
- 239000004615 ingredient Substances 0.000 claims abstract description 24
- 230000001580 bacterial effect Effects 0.000 claims abstract description 23
- 229940086319 nattokinase Drugs 0.000 claims abstract description 22
- 108010073682 nattokinase Proteins 0.000 claims abstract description 22
- 239000012503 blood component Substances 0.000 claims abstract description 15
- 239000013589 supplement Substances 0.000 claims abstract description 10
- 230000006870 function Effects 0.000 claims description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 67
- 201000010099 disease Diseases 0.000 claims description 62
- 229940079593 drug Drugs 0.000 claims description 44
- 235000013305 food Nutrition 0.000 claims description 30
- 206010010774 Constipation Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 241000894007 species Species 0.000 claims description 17
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 13
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 13
- 208000026278 immune system disease Diseases 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 235000004347 Perilla Nutrition 0.000 claims description 10
- 206010003805 Autism Diseases 0.000 claims description 9
- 208000020706 Autistic disease Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 229920001277 pectin Polymers 0.000 claims description 8
- 235000010987 pectin Nutrition 0.000 claims description 8
- 239000001814 pectin Substances 0.000 claims description 8
- 230000008085 renal dysfunction Effects 0.000 claims description 8
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 7
- 229920002581 Glucomannan Polymers 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000000783 alginic acid Substances 0.000 claims description 7
- 229960001126 alginic acid Drugs 0.000 claims description 7
- 150000004781 alginic acids Chemical class 0.000 claims description 7
- 229940046240 glucomannan Drugs 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 229920002488 Hemicellulose Polymers 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010058359 Hypogonadism Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 239000003440 toxic substance Substances 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 229920001543 Laminarin Polymers 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 238000006065 biodegradation reaction Methods 0.000 claims description 5
- 208000010706 fatty liver disease Diseases 0.000 claims description 5
- 239000000575 pesticide Substances 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 244000124853 Perilla frutescens Species 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 claims description 4
- 230000003818 metabolic dysfunction Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229920002752 Konjac Polymers 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 239000004009 herbicide Substances 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 239000000252 konjac Substances 0.000 claims description 3
- 235000010485 konjac Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000027758 ovulation cycle Effects 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 239000005060 rubber Substances 0.000 claims description 3
- 230000036301 sexual development Effects 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 150000001555 benzenes Chemical class 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- WEHZQLDFDZDFRZ-UHFFFAOYSA-N ethylamino benzoate Chemical compound CCNOC(=O)C1=CC=CC=C1 WEHZQLDFDZDFRZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 239000000383 hazardous chemical Substances 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 2
- 244000018633 Prunus armeniaca Species 0.000 claims 1
- 235000009827 Prunus armeniaca Nutrition 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 150000003738 xylenes Chemical class 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 34
- 230000002708 enhancing effect Effects 0.000 abstract description 12
- 230000003393 splenic effect Effects 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 97
- 230000008859 change Effects 0.000 description 66
- 210000002966 serum Anatomy 0.000 description 65
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 56
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 56
- 210000004369 blood Anatomy 0.000 description 37
- 239000008280 blood Substances 0.000 description 37
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 32
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 28
- 229940109239 creatinine Drugs 0.000 description 28
- 229940116269 uric acid Drugs 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 26
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 25
- 230000009471 action Effects 0.000 description 24
- 230000006872 improvement Effects 0.000 description 23
- 230000002159 abnormal effect Effects 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 21
- 230000004060 metabolic process Effects 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 230000036541 health Effects 0.000 description 17
- 235000000346 sugar Nutrition 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 108010028554 LDL Cholesterol Proteins 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000024924 glomerular filtration Effects 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 13
- 230000003907 kidney function Effects 0.000 description 13
- 230000007774 longterm Effects 0.000 description 13
- 230000000813 microbial effect Effects 0.000 description 13
- 241000605059 Bacteroidetes Species 0.000 description 12
- 241000192125 Firmicutes Species 0.000 description 12
- 229940076279 serotonin Drugs 0.000 description 12
- 230000004936 stimulating effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000002457 bidirectional effect Effects 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 208000030159 metabolic disease Diseases 0.000 description 11
- 241000425347 Phyla <beetle> Species 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 239000006041 probiotic Substances 0.000 description 10
- 235000018291 probiotics Nutrition 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 230000003908 liver function Effects 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 206010000060 Abdominal distension Diseases 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 8
- 208000017667 Chronic Disease Diseases 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002676 xenobiotic agent Substances 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 7
- 102000003929 Transaminases Human genes 0.000 description 7
- 108090000340 Transaminases Proteins 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000033077 cellular process Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 7
- 230000035790 physiological processes and functions Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 108091005685 RIG-I-like receptors Proteins 0.000 description 6
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- -1 include Chemical compound 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000037353 metabolic pathway Effects 0.000 description 6
- 229930001119 polyketide Natural products 0.000 description 6
- 229960000187 tissue plasminogen activator Drugs 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000305071 Enterobacterales Species 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010219 correlation analysis Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 102000003849 Cytochrome P450 Human genes 0.000 description 4
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 4
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 241000520272 Pantoea Species 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 240000004534 Scutellaria baicalensis Species 0.000 description 4
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000024330 bloating Diseases 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000012252 genetic analysis Methods 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 229960005356 urokinase Drugs 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 241000192142 Proteobacteria Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009131 signaling function Effects 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014486 Elevated triglycerides Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 241000160321 Parabacteroides Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000037362 glycan biosynthesis Effects 0.000 description 2
- 230000007149 gut brain axis pathway Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000001724 microfibril Anatomy 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 2
- 150000003881 polyketide derivatives Chemical class 0.000 description 2
- 125000000830 polyketide group Chemical group 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 108010073863 saruplase Proteins 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000000576 supplementary effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000002034 xenobiotic effect Effects 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000222501 Agaricaceae Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 108091007403 Cholesterol transporters Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 244000090599 Plantago psyllium Species 0.000 description 1
- 235000010451 Plantago psyllium Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- NHELFTYSELEEFD-SVAWBNMMSA-N Yuanhuadine Chemical compound O[C@H]([C@@]1(CO)O[C@H]1[C@H]1[C@H]2O3)[C@]4(O)C(=O)C(C)=C[C@H]4[C@]11O[C@@]3(/C=C/C=C/CCCCC)O[C@@]2(C(C)=C)[C@H](OC(C)=O)[C@H]1C NHELFTYSELEEFD-SVAWBNMMSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- CGSGRJNIABXQJQ-NSCQCFIPSA-N chembl504425 Chemical compound O([C@@H]1[C@@H](C)[C@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]2[C@H]2O[C@@](O3)(O[C@]21C(C)=C)/C=C/C=C/CCCCC)C(=O)C1=CC=CC=C1 CGSGRJNIABXQJQ-NSCQCFIPSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000037347 glycan metabolism Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001374 post-anti-biotic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001812 small ribosome subunit Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- RMRCNWBMXRMIRW-WYVZQNDMSA-L vitamin b12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- CGSGRJNIABXQJQ-OYICXTIPSA-N yuanhuacine Natural products CCCCCC=CC=C[C@]12O[C@@H]3[C@@H]4[C@@H]5O[C@]5(CO)[C@@H](O)[C@@]6(O)[C@@H](C=C(C)C6=O)[C@@]4(O1)[C@H](C)[C@@H](OC(=O)c7ccccc7)[C@@]3(O2)C(=C)C CGSGRJNIABXQJQ-OYICXTIPSA-N 0.000 description 1
- NHELFTYSELEEFD-VIWDXOHVSA-N yuanhuadine Natural products CCCCCC=CC=C[C@]12O[C@@H]3[C@@H]4[C@@H]5O[C@]5(CO)[C@@H](O)[C@@]6(O)[C@@H](C=C(C)C6=O)[C@@]4(O1)[C@H](C)[C@@H](OC(=O)C)[C@@]3(O2)C(=C)C NHELFTYSELEEFD-VIWDXOHVSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
Abstract
Description
個別化腸内細菌叢の多様性を整える機能を有する組成物であって、脾の機能を高めて気を補う成分と、除湿活血成分と、腸内細菌エネルギー源を含む。
好ましくは、前記腸内細菌エネルギー源は水溶性食物繊維、非水溶性食物繊維又は両者の任意の組み合わせを含むがこれらに限定されない。
本発明において、1日量は1回または2回以上に分けて服用することができる。
より好ましい解決手段として、1日量の主な成分は以下のとおりである。
具体的な好ましい解決手段として、1日量で計算し、前記組成物は以下の成分を含む。
オタネニンジン又はアメリカニンジンのうちの一種又は複数種の混合物0.1~1g
ブクリョウ 0.5~4g
納豆キナーゼ 500~4000Fu
グアーガム 0.05~0.4g
アルギン酸 0.05~0.4g
ラミナラン 0.05~0.4g
チンピ 0.05~0.4g
グルコマンナン 0.1~0.8g
プシリウム種皮 0.25~2g
ラカンカ0.35~1.4g。
具体的な好ましい解決手段として、1日量で計算し、前記組成物は以下の成分を含む。
オタネニンジン抽出物又はアメリカニンジン抽出物のうちの一種又は二種の混合物 0.01~0.04g
ブクリョウ 0.5~4g
ナットウキナーゼ 500~4000Fu
グアーガム 0.05~0.4g
アルギン酸 0.05~0.4g
ラミナラン 0.05~0.4g
チンピ 0.05~0.4g
グルコマンナン 0.1~0.8g
プシリウム種皮 0.25~2g
ラカンカ0.35~1.4g。
好ましくは、前記腸内細菌叢の不均衡は腸内細菌叢の種類及び機能の多様性の低下を含む。
好ましくは、前記代謝機能異常性疾患は境界型糖尿病、II型糖尿病、肥満、心血管疾患、脳血管疾患、脂質異常症、高血圧、高尿酸、腎機能障害を含む。
好ましくは、前記皮膚系疾患は腸内細菌叢の不均衡に関連するアトピー性皮膚炎、乾癬、湿疹、ざ瘡、肌荒れ、皮膚老化を含む。
好ましくは、前記精神神経系疾患はうつ病、双極性障害、自閉症、統合失調症、筋線維痛症、不眠症、パーキンソン病、アルツハイマー病を含む。
好ましくは、前記消化器系疾患は便秘、下痢、脂肪肝、肝硬変を含む。
組成物の説明は以下のとおりである。組成物1~6に、キョウニン(0.25~1g)及びシソシ(0.25~1g)を加えて佐薬とする。腸内細菌叢の不均衡に漢方医による腸燥便秘の診断が伴う人に適する。漢方医の診断に基づいて、柔軟に使用する。キョウニンは食物繊維の含有量が10%を超え、豊富に含まれる不飽和脂肪酸は整腸作用を有する。シソシは、不飽和脂肪酸(>50%)および必須アミノ酸を豊富に含む。すなわち腸内細菌叢にエネルギー基質を供給することができ、腸燥便秘に対して腸を整えて便通を促す作用も有する。
ここで、除湿成分はブクリョウの生薬又は抽出物を含むがこれらに限定されない。
ここで、活血成分はナットウキナーゼ、納豆の生薬又は抽出物を含むがこれらに限定されない。
ここで、非水溶性食物繊維はセルロース、ヘミセルロース、リグノセルロースのうちの一種又は複数種を含むがこれらに限定されない。
試験方法:
米国国立コレステロール教育プログラム(Third Report of the National Cholesterol Education Program (NCEP),NIH Publication No.02-5215)に基づいて、治験ボランティアを正常群と異常群に分ける。服用前および30日間の服用後に血液検査を受ける。検査前日の夜9時以降は、飲用水を除き、如何なる食物の摂取も禁止である。血清コレステロールはコレステロールオキシダーゼ法を用い、トリグリセリドはGPO-PAP酵素法を用いて病院分析室で通常の測定を行う。
正常及び異常な血液検出指標はそれぞれ以下の表に示すとおりである。
正常群16名、異常群14名の合計30名の治験ボランティアの基本的な状況及び投薬前後のデータ変化リストは以下のとおりである。
血清総コレステロールは血液中のリポタンパク質に含まれるコレステロールの和であり、低比重リポタンパク質コレステロール及び高比重リポタンパク質コレステロールはその主要な成分である。該発明は、低比重リポタンパク質コレステロールが正常である治験ボランティア12名、異常である治験ボランティア18名、合計30名の治療効果を観察した。治験ボランティアの基本的な状況及び投薬前後のデータ変化リストは以下のとおりである。
<トリグリセリドに対する作用>
<空腹時血糖の改善作用>
試験方法:
試験方法:
血清尿酸≧420μmol/L(男性)、≧360μmol/L(女性)の治験ボランティアを血清尿酸異常群とし、該レベルより低いものを血清尿酸正常群とする(Liu AD et al,J Atheroscler. Theromb. 2013)。以下の表は血清尿酸正常群(15名)、血清尿酸異常群(13名)の合計28名の治験ボランティアの基本的な状況及び投薬前後の血清尿酸値の変化である。治験ボランティアには服用前と30日間の服用後に血液検査を行う。検査前日の夜9時以降は、飲用水を除き、如何なる食物の摂取も禁止である。血清尿酸は酵素カップリング法で測定した。
試験方法:
血清クレアチニン及び糸球体濾過量は肝機能を測定するための基本的な方法である。該発明は血清クレアチニンレベルの検出及び糸球体濾過量の計算を利用して、該組成物の腎機能に対する改善作用を証明する。治験ボランティアには服用前と30日間の服用後に血液検査を行う。検査前日の夜9時以降は、飲用水を除き、如何なる食物の摂取も禁止である。検査日の朝、クレアチニン酵素法を用い静脈から採取して血清クレアチニンレベルを通常通り測定する。下表は23名の治験ボランティアの基本的な状況及び投薬前後の血清クレアチニンレベルの変化である。
計算方法
上記血清クレアチニン測定値から、中国改良版法を用いて計算し、推算糸球体濾過量糸球体濾過量(eGFR)を得た。eGFR<90mi/Lは糸球体濾過量異常群である。下表は治験ボランティアの基本情報及び服用後のデータ変化である。
試験方法:
該発明は、非アルコール性脂肪肝の研究で取得した肝細胞障害の指標閾値(Bedogni G et al. Hepatology 2005)を用いて、グルタミン酸ピルビン酸トランスアミナーゼ又はグルタミン酸オキサロ酢酸トランスアミナーゼ>30U/Lの治験ボランティアを対象とし、服用前及び30日間服用した後の変化を観察した。検査前日の夜9時以降は、飲用水を除き、如何なる食物の摂取も禁止である。検査日の朝、初速度分析法を用い、静脈血を採取してグルタミン酸ピルビン酸トランスアミナーゼ又はグルタミン酸オキサロ酢酸トランスアミナーゼ活性を測定する。下表は10名の治験ボランティアの基本的な状況及び服用前後のグルタミン酸ピルビン酸トランスアミナーゼ又はグルタミン酸オキサロ酢酸トランスアミナーゼ活性の変化である。
Claims (25)
- 脾の機能を高めて気を補う成分と、除湿活血成分と、腸内細菌エネルギー源と、を含むことを特徴とする、個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 前記脾の機能を高めて気を補う成分はオタネニンジン、オタネニンジン抽出物、アメリカニンジン、アメリカニンジン抽出物のうちの一種又は複数種を含むことを特徴とする、請求項1に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 前記除湿活血成分は除湿成分及び活血成分を含み、そのうち除湿成分はブクリョウ、ブクリョウ抽出物のうちの一種又は複数種の混合物を含み、活血成分はナットウキナーゼ、納豆、納豆抽出物のうちの一種又は複数種の混合物を含むことを特徴とする、請求項1に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 前記腸内細菌エネルギー源は水溶性食物繊維、非水溶性食物繊維又は両者の任意の組み合わせを含むことを特徴とする、請求項1に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 前記水溶性食物繊維はコンニャク粉、グルコマンナン、ラミナラン、ペクチン、アルギン酸、デキストラン、グアーガム、イヌリン、チンピのうちの一種又は複数種、又は上記の成分を含有する食材又は薬材のうちの一種又は複数種を含むことを特徴とする、請求項4に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 前記非水溶性食物繊維はセルロース、ヘミセルロース、リグノセルロースのうちの一種又は複数種を含むことを特徴とする、請求項4に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- さらにラカンカ、ラカンカ抽出物、キョウニン、キョウニン抽出物、シソシ、シソシ抽出物のうちの一種又は複数種を含むことを特徴とする、請求項1に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 前記脾の機能を高めて気を補う成分はオタネニンジン、オタネニンジン抽出物、アメリカニンジン、アメリカニンジン抽出物のうちの一種又は複数種であり、前記除湿活血成分は除湿成分及び活血成分を含み、そのうち除湿成分はブクリョウ、ブクリョウ抽出物のうちの一種又は複数種の混合物を含み、前記活血成分はナットウキナーゼ、納豆、納豆抽出物のうちの一種又は複数種の混合物を含み、1日量の主な成分は
表21
であり、
ここで、納豆又は納豆抽出物の添加量はその中に含まれるナットウキナーゼの酵素活性の単位に基づき計算することを特徴とする、請求項1~7のいずれか一項に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。 - さらにラカンカ0.1~3g又はラカンカ抽出物0.001~0.5gを含み、又は杏仁0.25~1g及び/又はシソシ0.25~1gを同時に又は単独で含むことを特徴とする、請求項8に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 水溶性食物繊維は配合総量の20%~60%を占め、非水溶性食物繊維は配合総量の20%~60%を占め、1日量で計算して、水溶性食物繊維又は非水溶性食物繊維の総添加量は1~10gであることを特徴とする、請求項1~10のいずれか一項に記載の個別化腸内細菌叢の多様性を整える機能を有する組成物。
- 請求項1~12のいずれか一項に記載の組成物の、個別化腸内細菌叢の多様性を整える機能を有する薬物、健康食品又は食品の製造における使用、又は腸内細菌叢の不均衡に関連する疾患の予防、又は治療、又は治療補助における使用。
- 前記薬物は腸内細菌叢の不均衡に関連する疾患の予防、又は治療、又は治療を補助する薬物であり、前記健康食品又は食品は腸内細菌叢の不均衡を改善する機能を有する健康食品又は食品であることを特徴とする、請求項13に記載の使用。
- 前記腸内細菌叢の不均衡は、腸内細菌叢の種類及び機能の多様性の低下を含むことを特徴とする、請求項14に記載の使用。
- 前記腸内細菌叢の不均衡は、優勢な腸内細菌叢の種類及び機能ゲノムが相対的に強く、劣勢の腸内細菌叢の種類及び機能ゲノムが相対的に弱いことを含むことを特徴とする、請求項14に記載の使用。
- 前記腸内細菌叢の不均衡に関連する疾患は腸内細菌叢の不均衡に関連する代謝機能異常性疾患、免疫機能異常性疾患、皮膚系疾患、精神神経系疾患、消化器系疾患、及び性ホルモン低下関連疾患のうちの一種又は複数種を含むことを特徴とする、請求項14に記載の使用。
- 前記代謝機能異常性疾患は境界型糖尿病、II型糖尿病、肥満、心血管疾患、脳血管疾患、脂質異常症、高血圧、高尿酸、腎機能障害のうちの一種又は複数種を含むことを特徴とする、請求項17に記載の使用。
- 前記免疫機能性疾患は食物/薬物/異物アレルギー、湿疹、I型糖尿病、過敏性腸症候群、炎症性腸疾患、クローン病、多発性硬化症、リウマチ、喘息、がんのうちの一種又は複数種を含むことを特徴とする、請求項17に記載の使用。
- 前記皮膚疾患は腸内細菌叢の不均衡に関連するアトピー性皮膚炎、乾癬、湿疹、ざ瘡、肌荒れ、皮膚老化のうちの一種又は複数種を含むことを特徴とする、請求項17に記載の使用。
- 前記精神神経系疾患はうつ病、双極性障害、自閉症、統合失調症、不眠症、パーキンソン病、アルツハイマー病、筋線維痛症のうちの一種又は複数種を含むことを特徴とする、請求項17に記載の使用。
- 前記消化器系疾患は便秘、下痢、脂肪肝、肝硬変を含むことを特徴とする、請求項17に記載の使用。
- 前記性ホルモン低下関連疾患は小児及び青少年の一次及び二次性徴発育遅延、女性の生理周期及び妊娠期の関連異常及び疾患、閉経後の女性のエストロゲン欠乏による骨粗鬆症、男女の性機能低下、及び更年期障害を含むことを特徴とする、請求項17に記載の使用。
- 前記薬物、健康食品又は食品は身体の外因性有毒物質に対する生分解機能を向上させる機能を有する薬物、健康食品又は食品であり、前記外因性有毒物質は農薬、除草剤、食品添加物、プラスチック残留物、ゴム残留物、環境汚染物質、重金属、および他の有害化学物質のうちの一種又は複数種を含むことを特徴とする、請求項13に記載の使用。
- 前記外因性有毒物質はハロゲン化安息香酸、ハロゲン化シクロヘキサン、ハロゲン化ベンゼン、カプロラクタム、2-クロロ-4-エチルアミノ-6-イソプロピルアミノ-1、3、5-トリアジン、ジオキシン、アミノ安息香酸エチル、キシレンのうちの一種又は複数種を含むことを特徴とする、請求項24に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911239497 | 2019-12-06 | ||
CN201911239497.1 | 2019-12-06 | ||
PCT/CN2020/130277 WO2021109879A1 (zh) | 2019-12-06 | 2020-11-20 | 具有健全个性化肠道菌群多样性功能的组合物及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023504493A true JP2023504493A (ja) | 2023-02-03 |
Family
ID=76162596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022532717A Pending JP2023504493A (ja) | 2019-12-06 | 2020-11-20 | 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220395551A1 (ja) |
EP (1) | EP4070819A4 (ja) |
JP (1) | JP2023504493A (ja) |
CN (1) | CN112915208B (ja) |
WO (1) | WO2021109879A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114391652B (zh) * | 2021-12-09 | 2023-08-22 | 中国农业科学院特产研究所 | 一种具有降血脂和调节肠道菌群结构功能的人参不溶性膳食纤维组合物及其制备方法与应用 |
CN116763812B (zh) * | 2023-08-17 | 2023-11-03 | 青岛农业大学 | 一种西洋参多糖及其制备的骨质疏松治疗药物和应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103315298A (zh) * | 2013-07-07 | 2013-09-25 | 安徽世茂中药股份有限公司 | 一种果蔬膳食纤维粉食品及其制备方法 |
CN103462029A (zh) * | 2013-07-18 | 2013-12-25 | 浙江劲膳美生物科技有限公司 | 一种脾虚气弱者食用的特殊膳食 |
CN103462093A (zh) * | 2013-07-18 | 2013-12-25 | 浙江劲膳美生物科技有限公司 | 一种排毒养颜者食用的特殊膳食 |
CN104172191A (zh) * | 2014-08-18 | 2014-12-03 | 胡安然 | 动脉粥样硬化全营养配方食品 |
CN104187741A (zh) * | 2014-08-15 | 2014-12-10 | 胡安然 | 心脏病全营养配方食品 |
CN104304912A (zh) * | 2014-10-25 | 2015-01-28 | 胡安然 | 脂肪瘤全营养配方食品 |
CN104839679A (zh) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 心脏病医学配方食品 |
CN105831749A (zh) * | 2016-04-15 | 2016-08-10 | 劲膳美生物科技股份有限公司 | 高血压医学配方食品 |
CN106307205A (zh) * | 2016-08-05 | 2017-01-11 | 司天攀 | 一种防治心脑血管性疾病的保健食品 |
CN108077912A (zh) * | 2017-12-25 | 2018-05-29 | 陕西三正医用营养有限公司 | 一种全营养特殊医学用途配方食品及其制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106259891A (zh) | 2015-05-28 | 2017-01-04 | 上海旺旺食品集团有限公司 | 一种益生菌口含片及其制备方法 |
MY187060A (en) | 2015-06-30 | 2021-08-28 | Perfect China Co Ltd | Bifidobacteria as probiotic foundation species of gut microbiota |
CN105535580A (zh) | 2015-12-21 | 2016-05-04 | 上海善力健生物科技有限公司 | 一种用于改善人体肠道菌群的生物制剂及其制备方法 |
CN105670047B (zh) | 2016-01-07 | 2018-04-13 | 南京财经大学 | 一种改善肠道微生物的金针菇多糖可食用膜 |
CN105505992A (zh) | 2016-01-08 | 2016-04-20 | 湖北省农业科学院农产品加工与核农技术研究所 | 益生菌复合生物发酵生产功能食品的方法 |
CN105596445A (zh) | 2016-01-13 | 2016-05-25 | 中国药科大学 | 丹皮赤芍在调节肠道菌群中的用途 |
IL243707A0 (en) * | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
CN105685868A (zh) | 2016-01-22 | 2016-06-22 | 湖南营养树科技有限公司 | 一种益生菌复配蔓越莓的女性生殖健康营养补充剂 |
CN105641521A (zh) | 2016-01-27 | 2016-06-08 | 扈嘉正 | 一种具有肠道清洁功效的口服粉剂 |
TWI587863B (zh) | 2016-01-29 | 2017-06-21 | Grape King Inc | A probiotic entrapping particle |
CN105532904A (zh) | 2016-02-17 | 2016-05-04 | 江苏微康生物科技有限公司 | 一种植物蛋白型浓缩益生菌发酵原液及其制备方法 |
CN105707628B (zh) | 2016-03-11 | 2019-03-08 | 三株福尔制药有限公司 | 一种益生菌发酵铁皮石斛原球茎的组合物及其制备方法 |
CN105969680B (zh) | 2016-03-23 | 2019-07-05 | 贵州大学 | 一株降胆固醇、降亚硝酸盐的戊糖乳杆菌及其筛选方法 |
CN105779343B (zh) | 2016-03-28 | 2019-05-10 | 济南康多宝生物技术有限公司 | 一株有效去除胆固醇和自由基的植物乳杆菌及其应用 |
CN105749099B (zh) | 2016-03-30 | 2019-09-13 | 三株福尔制药有限公司 | 一种治疗胃癌的益生菌发酵中药组合物及其制备方法和应用 |
CN105797003B (zh) | 2016-04-20 | 2019-08-06 | 三株福尔制药有限公司 | 一种治疗结肠癌的益生菌发酵中药复方组合物及其制备方法和应用 |
CN105962086B (zh) | 2016-05-06 | 2017-05-03 | 广州能靓生物技术有限公司 | 一种组合物及其在制备缓解胃部不适的保健品中的应用 |
CN106036856B (zh) | 2016-06-15 | 2019-06-04 | 杭州彧弋科技有限公司 | 一种高溶解性益生菌发酵石斛粉及其制备与应用 |
CN106072668A (zh) * | 2016-06-29 | 2016-11-09 | 傅志勇 | 排毒养颜的保健品及其制备方法 |
CN106942724B (zh) | 2017-03-23 | 2021-01-19 | 江苏省中医药研究院 | 具有调节肠道菌群结构作用的组合物及其制备方法与应用 |
CN106943423B (zh) | 2017-03-23 | 2019-08-27 | 江苏省中医药研究院 | 具有调节肠道菌群结构作用的多糖组合物及其应用 |
CN107115364B (zh) | 2017-04-22 | 2018-06-05 | 北京市永康年健康科技有限责任公司 | 一种复合益生菌及其制备方法 |
CN107468716B (zh) | 2017-08-24 | 2018-05-04 | 北京亦贝安生物医药科技有限公司 | 一种益生菌和益生元复方制剂及其加工方法 |
TWI658791B (zh) | 2017-09-25 | 2019-05-11 | 愛之味股份有限公司 | 具有調節血脂、改善腸道菌叢及提升免疫力功能的富含寡醣乳製品及其製法 |
TWI643625B (zh) | 2017-10-12 | 2018-12-11 | 國泰醫療財團法人國泰綜合醫院 | Intestinal probiotics for the preparation of a drug group for inhibiting the migration of colorectal cancer cells Use of the compound |
CN107495049B (zh) | 2017-10-17 | 2018-09-21 | 广东达明益派生物科技有限公司 | 一种具有润肠通便功能的饮料 |
CN108159201A (zh) | 2018-02-05 | 2018-06-15 | 陈霞 | 一种调节高脂人群肠道菌群的产品及其制备方法与应用 |
CN108159090A (zh) | 2018-03-14 | 2018-06-15 | 广东省微生物研究所(广东省微生物分析检测中心) | 灵芝孢子粉膳食纤维提取物在制备治疗和/或预防肠道菌群失调相关疾病制剂中的用途 |
CN108685005A (zh) | 2018-03-21 | 2018-10-23 | 大连东霖食品股份有限公司 | 一种调节肠道菌群平衡降三高的固体饮料 |
CN108741036A (zh) | 2018-06-19 | 2018-11-06 | 中国农业科学院特产研究所 | 一种具有调节肠道菌群功能的人参果胶组合物及其应用 |
CN109988725A (zh) | 2018-06-26 | 2019-07-09 | 银川尧玥生物科技有限公司 | 减肥降血脂微生物菌剂及其衍生物的制备技术与应用 |
CN108795823B (zh) | 2018-07-04 | 2019-04-09 | 中科宜康(北京)生物科技有限公司 | 一种改善女性孕产妇肠道菌群的益生菌的培养方法和应用 |
CN109566760A (zh) * | 2018-12-17 | 2019-04-05 | 珠海市微豆生物技术有限公司 | 一种具有溶栓作用的植物蛋白固体饮料及其制备方法 |
CN110214816A (zh) | 2019-07-11 | 2019-09-10 | 丁强 | 一种纳豆多肽豆奶粉方便食品及其制备方法 |
-
2020
- 2020-11-20 CN CN202011310357.1A patent/CN112915208B/zh active Active
- 2020-11-20 WO PCT/CN2020/130277 patent/WO2021109879A1/zh unknown
- 2020-11-20 US US17/782,659 patent/US20220395551A1/en active Pending
- 2020-11-20 EP EP20896431.2A patent/EP4070819A4/en not_active Withdrawn
- 2020-11-20 JP JP2022532717A patent/JP2023504493A/ja active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103315298A (zh) * | 2013-07-07 | 2013-09-25 | 安徽世茂中药股份有限公司 | 一种果蔬膳食纤维粉食品及其制备方法 |
CN103462029A (zh) * | 2013-07-18 | 2013-12-25 | 浙江劲膳美生物科技有限公司 | 一种脾虚气弱者食用的特殊膳食 |
CN103462093A (zh) * | 2013-07-18 | 2013-12-25 | 浙江劲膳美生物科技有限公司 | 一种排毒养颜者食用的特殊膳食 |
CN104187741A (zh) * | 2014-08-15 | 2014-12-10 | 胡安然 | 心脏病全营养配方食品 |
CN104172191A (zh) * | 2014-08-18 | 2014-12-03 | 胡安然 | 动脉粥样硬化全营养配方食品 |
CN104304912A (zh) * | 2014-10-25 | 2015-01-28 | 胡安然 | 脂肪瘤全营养配方食品 |
CN104839679A (zh) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 心脏病医学配方食品 |
CN105831749A (zh) * | 2016-04-15 | 2016-08-10 | 劲膳美生物科技股份有限公司 | 高血压医学配方食品 |
CN106307205A (zh) * | 2016-08-05 | 2017-01-11 | 司天攀 | 一种防治心脑血管性疾病的保健食品 |
CN108077912A (zh) * | 2017-12-25 | 2018-05-29 | 陕西三正医用营养有限公司 | 一种全营养特殊医学用途配方食品及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112915208A (zh) | 2021-06-08 |
US20220395551A1 (en) | 2022-12-15 |
EP4070819A4 (en) | 2023-01-25 |
WO2021109879A1 (zh) | 2021-06-10 |
EP4070819A1 (en) | 2022-10-12 |
CN112915208B (zh) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ni et al. | Lactic acid bacteria strains relieve hyperuricaemia by suppressing xanthine oxidase activity via a short-chain fatty acid-dependent mechanism | |
Henning et al. | Pomegranate ellagitannins stimulate the growth of Akkermansia muciniphila in vivo | |
Sun et al. | In vitro fermentation of κ-carrageenan oligosaccharides by human gut microbiota and its inflammatory effect on HT29 cells | |
Zhang et al. | Effects of Auricularia auricula and its polysaccharide on diet-induced hyperlipidemia rats by modulating gut microbiota | |
Ran et al. | Sea buckthorn (Hippophae rhamnoides L.) fermentation liquid protects against alcoholic liver disease linked to regulation of liver metabolome and the abundance of gut microbiota | |
Blatchford et al. | Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial | |
Ejtahed et al. | Targeting obesity management through gut microbiota modulation by herbal products: a systematic review | |
JP2023504493A (ja) | 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用 | |
Guo et al. | Advances in the mechanisms of polysaccharides in alleviating depression and its complications | |
JP2021519763A (ja) | 炎症性腸疾患を治療するための組成物及び方法 | |
Ren et al. | Ganoderma amboinense polysaccharide prevents obesity by regulating gut microbiota in high-fat-diet mice | |
Tang et al. | Qingke β-glucan synergizes with a β-glucan-utilizing Lactobacillus strain to relieve capsaicin-induced gastrointestinal injury in mice | |
Cao et al. | Soluble dietary fiber and cellulose from Saccharina japonica by-product ameliorate Loperamide-induced constipation via modulating enteric neurotransmitters, short-chain fatty acids and gut microbiota | |
Yang et al. | Bergamot polysaccharides relieve DSS-induced ulcerative colitis via regulating the gut microbiota and metabolites | |
Ren et al. | Stachyose in combination with L. rhamnosus GG ameliorates acute hypobaric hypoxia-induced intestinal barrier dysfunction through alleviating inflammatory response and oxidative stress | |
WO2022127934A1 (zh) | 人参皂苷在改善肠道菌群结构和/或肠屏障功能的应用 | |
Ren et al. | Fecal microbiota transplantation: whole grain highland barley improves glucose metabolism by changing gut microbiota | |
AU2020210564B2 (en) | A yeast product, and a composition comprising it, for use as a prebiotic agent | |
Xu et al. | Loganin regulates glycolipid metabolism by influencing intestinal microbiota and AMPK signaling in obese mice | |
Zhang et al. | Microbial modifications with Lycium barbarum L. oligosaccharides decrease hepatic fibrosis and mitochondrial abnormalities in mice | |
US20190307802A1 (en) | Probiotic compositions including immune modulators | |
US20230124503A1 (en) | Ginsenoside compositions | |
Morissette et al. | The metabolic benefits of substituting sucrose for maple syrup are associated with a shift in carbohydrate digestion and gut microbiota composition in high-fat high-sucrose diet-fed mice | |
EP3370751B1 (en) | Lentil extract with cholesterol lowering and prebiotic activity | |
Chi | Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240527 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240604 |